Gilead Sciences is on the the prowl for potential buyout targets. This little-known immuno-therapy company looks like a perfect match for the biotech in many ways. Here’s why.
Gilead Sciences is on the the prowl for potential buyout targets. This little-known immuno-therapy company looks like a perfect match for the biotech in many ways. Here’s why.